Business Context and Reporting Period
Air Products & Chemicals, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2008. The company is a large accelerated filer incorporated in Delaware. The report covers the third quarter and the first nine months of fiscal year 2008, comparing results to the same periods in 2007. The company operates globally with segments including Merchant Gases, Tonnage Gases, Electronics and Performance Materials, Equipment and Energy, and Healthcare.
Key Financial Metrics
| Metric | Q3 2008 | Q3 2007 | 9M 2008 | 9M 2007 |
|---|---|---|---|---|
| Sales | $2,808.0M | $2,416.2M | $7,886.9M | $6,982.0M |
| Operating Income | $67.6M | $352.4M | $777.8M | $978.4M |
| Net Income | $70.1M | $284.9M | $648.1M | $742.8M |
| Diluted EPS | $0.32 | $1.28 | $2.95 | $3.33 |
| Cash from Operations (9M) | $1,106.7M (2008) vs $809.9M (2007) | |||
| Total Debt | $4,030.0M (June 30, 2008) vs $3,670.9M (Sept 30, 2007) | |||
| Cash and Cash Items | $126.2M (June 30, 2008) vs $40.5M (Sept 30, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 16% in Q3 and 13% for the nine months ended June 30, 2008. Growth was driven by volume increases in Merchant Gases and Electronics, favorable currency effects (weaker U.S. dollar), and natural gas cost pass-throughs.
- Profitability Decline: Operating income dropped 81% in Q3 and 21% for the nine-month period. This decline was primarily due to a $314.8 million impairment charge related to the U.S. Healthcare business and a $28.7 million pension settlement charge.
- Discontinued Operations: The company completed the sale of its Polymer Emulsions business (generating an after-tax gain of $18.5M in Q3) and its High Purity Process Chemicals (HPPC) business. These are now reported as discontinued operations.
- Segment Performance:
- Merchant Gases: Sales up 19% and operating income up 20% due to volume and pricing.
- Tonnage Gases: Sales up 26% driven by natural gas cost pass-throughs.
- Healthcare: Reported an operating loss of $301.7M in Q3 due to the impairment charge.
- Equipment and Energy: Sales down 20% due to lower LNG activity.
Guidance, Outlook, and Risks
- 2008 Outlook: Management revised domestic manufacturing growth estimates to around 1% (down from 2-3%) and global growth to 2-3% (down from 3.5-4.0%). Capital expenditures are expected to be between $1,100M and $1,200M for 2008.
- Strategic Actions: The Board authorized the sale of the U.S. Healthcare business, which will be reported as a discontinued operation starting in Q4 2008. The company expects no material additional pension settlements in Q4.
- Risks and Contingencies:
- Legal: A Brazilian Ministry of Justice report recommends sanctions for alleged anticompetitive activities; the outcome is uncertain.
- Environmental: Accruals for environmental loss contingencies totaled $80.5M, with a reasonably possible upper exposure of $93M. Specific liabilities include remediation at the Pace, Florida facility ($39.6M) and the Piedmont, S.C. site ($24.0M).
- Market Risks: Sensitivity analysis indicates a 100 basis point increase in interest rates would decrease the net liability position of financial instruments by $102M.
Investor Verification Checklist
- Healthcare Divestiture: Verify the timeline and potential additional charges associated with the sale of the U.S. Healthcare business.
- Impairment Details: Confirm the non-cash nature of the $314.8M impairment charge and its impact on future tax positions.
- Environmental Liabilities: Review the feasibility study results for the Pace, Florida facility and the remediation timeline for the Piedmont site.
- Debt Structure: Assess the impact of the increased total debt ($4.03B) and the utilization of the $1.2B multicurrency revolving facility.
- Share Repurchases: Monitor the remaining capacity under the $1,000M share repurchase authorization (6.0M shares purchased in the first nine months).